MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Nanomedicine & Nanotechnology Open Access
ISSN: 2574-187X

Exosome Nanomedicine for Cancer Therapy

Sheikhhossein HH*

Department of Medical Biotechnology, G. d'Annunzio University, Italy

***Corresponding author:** Hamid Heydari Sheikhhossein, Department of Medical Biotechnology, G. d'Annunzio University, Italy; Tel: +39 3279828091, Email: hamid.heydari@unich.it

Editorial

Volume 10 Issue 3

Received Date: July 29, 2025

Published Date: September 30, 2025

DOI: 10.23880/nnoa-16000346

Editorial

A New Horizon in Cancer Nanotherapeutics

In recent decades, with the discovery of nanomedicine, new therapeutic strategies have been employed. Exosome-based therapies represent a promising platform for precision drug delivery, particularly in cancer treatment. These tiny vesicles are released by almost all types of cells, and due to their unique characteristics such as the ability to cross biological barriers, long circulation time, and active tissue targeting, they could be superior alternatives to synthetic drug carriers.

Keywords: Exosomes; Nanomedicine; Biological Nanocarriers; Immune Cell-Derived Vesicles; Drug Delivery

Abbreviations

RNA: Ribonucleic Acid; SCLC: Small-Cell Lung Carcinoma.

Introduction

Current Landscape and Emerging Trends

Despite the significant applications of conventional nanocarriers such as liposomes or polymeric and metallic particles, there are limitations to them. Their clinical efficiency is hindered due to issues like immune system activation and rapid degradation. Nevertheless, exosomes from endogenous sources have enabled the delivery of various therapeutic molecules such as RNA, proteins, and chemotherapeutic agents directly into target tissues.

Engineering exosomes is a new approach involving extracellular vesicles that can be isolated from cells exposed to specific conditions to express the desired molecules. Take immune cell- derived exosomes as an example which could retain a kind of 'biological memory' that enables them to recognize tumor antigens. By doing that, it would be possible to combine drug delivery with immune system modulation.

One of the valuable applications of this dual ability is in belligerent cancers like small-cell lung carcinoma (SCLC), where treatment needs to both suppress tumors and stimulate anti-cancer immunity.

Innovations in exosome research involve combining them with imaging agents to visualize drug distribution and assess treatment efficacy simultaneously, potentially transforming treatment monitoring and personalized medicine.

Challenges and Futures Prospects

Despite all the promising aforementioned applications of exosomes, there are several challenges in this field of study. Firstly, the isolation and purification of exosomes remain difficult processes. Even before that, scaling up production to clinical levels is a major technical bottleneck. Secondly, standardization is complex due to the biological variability shaped by their parental cells.

Nevertheless, it is possible to overcome these challenges by employing innovative technologies such as microfluidic systems, scalable bioreactors, and synthetic biology tools. Future nanomedicine aims to provide personalized, targeted treatments using patient-specific exosomes to minimize toxicity.

Conclusion

Exosomes, with their biocompatibility, targeted delivery, and versatility, promise to revolutionize cancer therapy as key components of next-generation treatments. It will take cooperative, multidisciplinary research that links immunology, materials science, molecular biology, and clinical trials to advance this frontier. With continued work and creativity, I think exosome-based treatments will soon make their way from the lab to the clinic.